Home›Stock Screener›Morepen Laboratories

Morepen Laboratories Share Price Today | Stock Price & Morepen Laboratories Share Screener

MOREPENLAB Pharmaceuticals
Live Share Price NSE
₹135.29
▲ 1.57 (1.17%)
2026-10-05 00:00:00
Live Share Price BSE
₹135.30
▲ 1.60 (1.20%)
2026-10-05 00:00:00

As of October 5, 2026, the live Morepen Laboratories share price (NSE: MOREPENLAB) is ₹135.29 on NSE and ₹135.30 on BSE, up 1.17% from the previous close, with shares trading between ₹130.46 and ₹137.64 in today's trading session, and a 52-week range of ₹33.68–₹135.29. Check MOREPENLAB price range for the annual price range and momentum. Use the Morepen Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Morepen Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹493 and net income of ₹16, with EBITDA of ₹33, an operating margin of 5.0% and a profit margin of 3.3%.

Morepen Laboratories Market Cap ₹7,327.24 Cr.
MOREPENLAB P/E Ratio (TTM) 49.03
Morepen Laboratories P/B Ratio 5.54
EPS (TTM) ₹1.73
Dividend Yield 0.16%
Debt to Equity 0.13
MOREPENLAB 52 Week High ₹135.29
Morepen Laboratories 52 Week Low ₹33.68
Operating Margin 5.00%
Profit Margin 3.25%
MOREPENLAB Revenue (TTM) ₹493.00
EBITDA ₹33.00
Net Income ₹16.00
Total Assets ₹1,936.00
Total Equity ₹1,247.00

Morepen Laboratories Share Price Chart

Track the current stock price of Morepen Laboratories with an interactive chart. Analyse MOREPENLAB share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Morepen Laboratories stock quote in one place.

The quote of ₹135.29 sits between the 52-week low of ₹33.68 and the 52-week high of ₹135.29, and the latest session moved 1.17% from the previous close.

Morepen Laboratories Company Profile - Fundamental Screener

Screen Morepen Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for MOREPENLAB shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE083A01026.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE083A01026

Morepen Laboratories Balance Sheet Screener

Screen MOREPENLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹1,936, up from ₹1,778 in 2025.

Latest statistics put total assets at ₹1,936 and shareholder funds at ₹1,247, with a leverage ratio of 0.13.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 1,936 1,778 1,293 1,111 1,070 858 664 615 586 538
Current Assets 1,164 1,159 889 756 734 527 372 300 243 192
Fixed Assets 513 489 307 267 252 225 216 236 264 272

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 199 91 44 37 36 30 28 23 20 18
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 1,247 1,187 847 752 578 424 284 253 226 196
Share Capital 110 110 102 102 96 90 90 90 90 90
Reserves & Surplus 1,137 1,047 745 651 457 291 194 163 136 106

Morepen Laboratories Income Statement Screener - Profit & Revenue Analysis

Screen Morepen Laboratories income statement and profit fundamentals. Analyze MOREPENLAB quarterly results. Morepen Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹493 and net profit was ₹16, equal to earnings per unit of ₹0.28, at an operating margin of 5%.

In that period expenses were ₹460, interest cost ₹4 and tax ₹8. The next period listed, 2026-Jun, shows revenue of ₹575 and net profit of ₹56.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar

Revenue and Expenses

Revenue 493 575 471 430 442 488 427 459 443 458 367 404 425 449 372
Expenses 460 488 424 401 381 438 375 404 394 417 348 375 388 394 350

Operating Costs and Margins

EBITDA 33 88 47 29 61 50 53 55 49 42 19 29 37 55 22
Operating Profit % 5.00% 14.00% 9.00% 6.00% 7.00% 10.00% 11.00% 11.00% 10.00% 8.00% 4.00% 7.00% 8.00% 11.00% 5.00%
Depreciation 6 8 17 9 11 10 10 6 2 5 7 8 8 8 7
Interest 4 5 5 4 4 4 1 1 1 1 1 0 1 2 1

Profit and Earnings

Profit Before Tax 23 75 26 16 46 35 42 48 46 35 11 21 29 44 14
Tax 8 18 5 4 5 8 14 12 11 9 3 6 7 12 2
Net Profit 16 56 20 11 41 28 29 36 35 27 8 15 21 32 12
EPS 0.28 1.03 0.35 0.20 0.75 0.50 0.54 0.71 0.65 0.49 0.16 0.29 0.42 0.63 0.27

Morepen Laboratories Cash Flow Screener - Liquidity Fundamentals

Screen MOREPENLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹33, and net cash flow was an inflow of ₹4.

Over the same period, investing activities used ₹126 and financing activities provided ₹97.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 33 32 73 -91 -60 51 11 17 63 41
Investing Activities -126 -322 -83 -47 -32 -70 -13 -13 -27 -14

Financing and Net Cash

Financing Activities 97 300 5 144 66 47 6 0 -38 -24
Net Cash Flow 4 10 -5 6 -26 28 4 4 -1 3

Morepen Laboratories Shareholding Pattern Screener

See Morepen Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Morepen Laboratories promoter holding and ownership changes for MOREPENLAB on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 35.65%, foreign institutions 1.59%, domestic institutions 1.25% and the public 50.03%, spread across 447,286 shareholders.

The shareholder count was 447,286 in 2026-Mar, compared with 434,912 in 2026-Jun.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun

Promoter Holding

Promoter Holding 35.65% 35.65% 35.65% 35.65% 35.65% 35.65% 38.22% 38.22%

Institutional Investors

FII Holding 1.59% 1.46% 1.94% 1.72% 1.62% 1.62% 1.85% 1.67%
DII Holding 1.25% 1.28% 1.67% 1.51% 1.50% 1.25% 2.15% 2.15%

Government, Public and Others

Govt Holding 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
Public Holding 50.03% 49.75% 48.76% 49.35% 49.96% 50.28% 45.03% 45.22%
Other Holding 11.47% 11.84% 11.96% 11.76% 11.26% 11.18% 12.74% 12.74%
Shareholder Count 447,286 434,912 468,860 461,180 461,853 453,137 336,019 348,766

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Morepen Laboratories. Morepen Laboratories dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.20 per unit for 2026-March, a yield of 0.17%, compared with ₹0.20 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.20, ₹0.20 and ₹0.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.20 0.17%
2025-March ₹0.20 0.59%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹0.00 0.00%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Morepen Laboratories Stock Index Membership - Nifty & Sensex

See which indices include Morepen Laboratories stock. Check MOREPENLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 3 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP

Morepen Laboratories Market Events Screener - Corporate Actions

Get Morepen Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Morepen Laboratories stock events that may affect MOREPENLAB share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Annual General Meeting dated September 26, 2026, with a record date of September 26, 2026.

It is followed by Dividend dated September 18, 2026 and Quarterly Result Announcement dated August 4, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-09-26 2026-09-26 Annual General Meeting NA 108.82%
2026-09-18 2026-09-19 Dividend ₹ 0.20 /share 176.41%
2026-08-04 2026-08-04 Quarterly Result Announcement NA 1.80%
2026-05-26 2026-05-26 Quarterly Result Announcement NA 1.70%
2026-02-10 2026-02-10 Quarterly Result Announcement NA 10.03%
2025-11-14 2025-11-14 Quarterly Result Announcement NA -1.79%
2025-09-06 2025-09-06 Annual General Meeting NA -12.82%
2025-08-29 2025-08-30 Dividend ₹ 0.20 /share -17.00%
2025-08-06 2025-08-06 Quarterly Result Announcement NA -3.23%
2025-05-12 2025-05-12 Quarterly Result Announcement NA -5.11%
2025-02-10 2025-02-10 Extraordinary General Meeting NA -10.10%
2025-02-06 2025-02-06 Quarterly Result Announcement NA 3.02%
2024-11-11 2024-11-11 Quarterly Result Announcement NA 1.20%
2024-09-28 2024-09-28 Annual General Meeting NA -9.94%
2024-03-18 2024-03-18 Extraordinary General Meeting NA -21.28%

Morepen Laboratories Competitors Screener - Peer Stocks Comparison

Screen MOREPENLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 432,120 36.04 61,674 12.69% 11,565 36.68
Divis Laboratories 245,532 84.24 11,067 13.95% 2,568 51.70
Torrent Pharmaceuticals 181,333 84.71 13,886 20.34% 2,138 41.12
Zydus Life Science 114,284 25.27 27,658 17.64% 5,026 47.64
Cipla 108,576 32.50 29,045 2.24% 3,870 34.78
Laurus Labs 107,198 98.20 6,868 22.01% 890 58.70
Mankind Pharma 104,707 50.04 14,636 14.85% 1,938 61.75
Dr Reddys Laboratories 100,679 32.41 35,059 3.90% 4,158 53.84
Aurobindo Pharma 96,479 25.84 34,145 5.56% 3,503 50.30
Lupin 92,885 16.82 29,039 26.75% 5,356 31.59

Morepen Laboratories Company Announcements - News & Reports Screener

Screen MOREPENLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 2, 2026.

The next most recent announcements are dated October 2, 2026 and September 30, 2026.

Date Update Actions
2026-10-02 Closure of Trading Window -
2026-10-02 Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) -
2026-09-30 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-30 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-26 Intimation Regarding ESG Rating -
2026-09-07 Announcement Under Regulation 30 Of The SEBI (LODR) -
2026-09-03 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-02 Letter To The Members (No E-Mail Id Registered) Comprising Weblink Of The Annual Report: 2025-26 -
2026-09-02 Business Responsibility and Sustainability Reporting (BRSR) -
2026-09-02 Notice Of 41St Annual General Meeting -
2026-09-02 Reg. 34 (1) Annual Report. -
2026-08-26 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-06 Announcement under Regulation 30 (LODR)-Acquisition -
2026-08-05 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-04 Announcement under Regulation 30 (LODR)-Monitoring Agency Report -
2026-08-04 Intimation Of Annual General Meeting -
2026-08-04 Announcement under Regulation 30 (LODR)-Change in Management -
2026-08-04 Intimation Of Record Date For Payment Of Final Dividend I.E. September 19 2026 -
2026-08-04 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-08-04 Announcement under Regulation 30 (LODR)-Investor Presentation -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹135.29, within a 52-week range of ₹33.68 to ₹135.29. The P/E ratio is 49.03 and the P/B ratio is 5.54, with earnings per unit of ₹1.73. Market capitalisation stands at ₹7,327.24 Cr and the dividend yield is 0.16%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 4, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.